CHRISTIAN KLEIN,PABLO UMANA,ANDREW G. POLSON,SABINE LANG
申请号：
MX2015015091
公开号：
MX2015015091A
申请日:
2014.04.30
申请国别(地区):
MX
年份:
2016
代理人:
摘要：
The present disclosure is directed to the combination therapy of an afucosylated anti-CD20 antibody with a CD79b antibody-drug conjugate for the treatment of cancer, especially to the combination therapy of CD20 expressing cancers with an afucosylated humanized B-Lyl antibody and a CD79b antibody-drug conjugate. The invention relates to inhibitors of the NHR2 tetramerization and their use as tumor therapeutics (e.g. against acute myeloid leukemia (AML)), cytostatics, and diagnostic agents. The present disclosure is directed to the combination therapy of an afucosylated anti-CD20 antibody with a CD79b antibody-drug conjugate for the treatment of cancer, especially to the combination therapy of CD20 expressing cancers with an afucosylated humanized B-Lyl antibody and a CD79b antibody-drug conjugate.La presente invención se refiere a la terapia de combinación de un anticuerpo anti-CD20 afucosilado con un conjugado de anticuerpo para CD79b-fármaco para el tratamiento de cáncer, especialmente a la terapia de combinación de cánceres que expresan CD20 con un anticuerpo B-Ly1 humanizado afucosilado y un conjugado de anticuerpo para CD79b-fármaco.
